Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ironwood Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 317 staff and has a trailing 12-month revenue of around USD$426.8 million.
Since the stock market crash in March caused by coronavirus, Ironwood Pharmaceuticals's share price has had significant positive movement.
Its last market close was USD$11.81, which is 1.52% up on its pre-crash value of USD$11.63 and 47.81% up on the lowest point reached during the March crash when the shares fell as low as USD$7.99.
If you had bought USD$1,000 worth of Ironwood Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$768.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$944.80.
|Latest market close||USD$11.81|
|52-week range||USD$7.99 - USD$14.1|
|50-day moving average||USD$9.79|
|200-day moving average||USD$10.0728|
|Wall St. target price||USD$10.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.615|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||1.99%|
|1 month (2020-10-23)||22.51%|
|3 months (2020-08-25)||11.52%|
|6 months (2020-05-22)||-1.34%|
|1 year (2019-11-25)||-3.20%|
|2 years (2018-11-23)||-9.29%|
|3 years (2017-11-24)||-24.49%|
|5 years (2015-11-25)||-3.67%|
Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Ironwood Pharmaceuticals shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$167.7 million.
The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$426.8 million|
|Operating margin TTM||38.03%|
|Gross profit TTM||USD$293 million|
|Return on assets TTM||26.72%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.6 billion|
TTM: trailing 12 months
There are currently 20.6 million Ironwood Pharmaceuticals shares held short by investors – that's known as Ironwood Pharmaceuticals's "short interest". This figure is 1% down from 20.8 million last month.
There are a few different ways that this level of interest in shorting Ironwood Pharmaceuticals shares can be evaluated.
Ironwood Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ironwood Pharmaceuticals shares currently shorted divided by the average quantity of Ironwood Pharmaceuticals shares traded daily (recently around 1.6 million). Ironwood Pharmaceuticals's SIR currently stands at 12.62. In other words for every 100,000 Ironwood Pharmaceuticals shares traded daily on the market, roughly 12620 shares are currently held short.
However Ironwood Pharmaceuticals's short interest can also be evaluated against the total number of Ironwood Pharmaceuticals shares, or, against the total number of tradable Ironwood Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ironwood Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Ironwood Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.2013% of the tradable shares (for every 100,000 tradable Ironwood Pharmaceuticals shares, roughly 201 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ironwood Pharmaceuticals.
Find out more about how you can short Ironwood Pharmaceuticals stock.
We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.
Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 2 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.
Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $7.99 up to $14.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 1.4346. This would suggest that Ironwood Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.